March 2025 Tender Notification
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2024/25 Invitation to Tender dated 31 October 2024.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on the 12th of April 2025 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines.(external link)
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
- 28 March 2025 Tender Notification [PDF 183 KB]
2024/25 Tender – Principal Supply Status applies until 30 June 2028
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
- Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
|---|---|---|---|---|---|---|---|
|
Neostigmine metisulfate with glycopyrronium bromide |
Inj 2.5 mg with glycoyrronium bromide 0.5 mg per ml, 1 ml ampoule; 10 ampoule pack |
$26.13 |
$26.13 |
Max Health (Max Health) |
5% |
1 September 2025 |
1 February 2026 |
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2024/25 Invitation to Tender, dated 31 October 2024.
|
Chemical Name |
Line Item |
|---|---|
|
Acetic acid with hydroxyquinoline and ricinoleic acid |
Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator |
|
Piperacillin with Tazobactam |
Inj 2 g with tazobactum 2000/250 mg |
|
Propylthiouracil |
Tab 50 mg |
|
Ropinirole hydrochloride |
Tab 0.25 mg |
|
Ropinirole hydrochloride |
Tab 1 mg |
|
Ropinirole hydrochloride |
Tab 2 mg |
|
Ropinirole hydrochloride |
Tab 5 mg |
|
Telmisartan |
Tab 40 mg |
|
Telmisartan |
Tab 80 mg |
|
Telmisartan with amlodipine |
Tab 40 mg with amlodipine 10 mg |
|
Telmisartan with amlodipine |
Tab 40 mg with amlodipine 5 mg |
|
Telmisartan with amlodipine |
Tab 80 mg with amlodipine 10 mg |
|
Telmisartan with amlodipine |
Tab 80 mg with amlodipine 5 mg |
|
Tenecteplase |
Inj 50 mg |
For products included in the 2022/23, 2023/24 and 2024/25 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.